secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-055781
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q1 net loss $39.1M; cash $293.8M; Novartis deal advances BRC pipeline
--------------------------------------------------------------------------------

- Net loss of $39.1M ($1.30 per share) vs $27.6M ($0.93 per share) in Q1 2022.
- R&D expenses rose to $32.2M from $14.3M, driven by BT8009, BT5528, and TICA programs.
- Cash $293.8M at March 31, 2023 (excluding $50M Novartis upfront); runway into 2025.
- Entered Novartis collaboration for Bicycle radio-conjugates; eligible for up to $1.7B milestones.
- BT8009 Phase I dose escalation showed median duration of response ~14 months in urothelial cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923055781/0001104659-23-055781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923055781/tm2314590d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-055781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer